Peptide Graded

Fragment 176-191

Is Fragment 176-191 legal in the US?

No. It is not approved and is sold as a research chemical.

CAnimal and cell studiesNot approvedas of 2026-10-26

Not approved by the FDA for any use and sold as a research chemical. A stabilized version with a tyrosine added, AOD9604, went through six company-run trials between 2001 and 2006, but only their safety data were published. 6

No. Under the name AOD9604 it went through phase 2 obesity trials in Australia, which failed. No one ever submitted it to any regulator for approval. 4

Read the full Fragment 176-191 page

More on Fragment 176-191

Citations

  1. Wu and Ng 1993, Biochemistry and Molecular Biology International: antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone pubmed.ncbi.nlm.nih.gov
  2. Ng 2000, Hormone Research: metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone pubmed.ncbi.nlm.nih.gov
  3. Heffernan 2001, International Journal of Obesity: increase of fat oxidation and weight loss in obese mice with growth hormone or a modified C-terminal fragment pubmed.ncbi.nlm.nih.gov
  4. Kakkar and Dahiya 2013, Current Cardiology Reviews: obesity pharmacotherapy, current perspectives and future directions pubmed.ncbi.nlm.nih.gov
  5. Ng 2000, Hormone Research: metabolic studies of AOD9604 (DOI record) doi.org
  6. Stier 2013, Journal of Endocrinology and Metabolism: safety and tolerability of the hexadecapeptide AOD9604 in humans doi.org

Reference information only, not medical advice. Drawn from the Fragment 176-191 article, fact-checked against the cited sources. No dosing anywhere on this site.